Statin use and risk for primary liver cancer in the clinical practice research datalink

Journal of the National Cancer Institute

Volumn 107, Issue 4, 2015, Pages

  McGlynn, Katherine A ^a   Hagberg, Katrina ^b   Chen, Jie ^a   Graubard, Barry I ^a   London, W Thomas ^c,d   Jick, Susan ^b   Sahasrabuddhe, Vikrant V ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d HEPATITIS B FOUNDATION   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CANCER RISK; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; LIVER CANCER; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK REDUCTION; UNITED KINGDOM; VERY ELDERLY; CASE CONTROL STUDY; COMPLICATION; DIABETES COMPLICATIONS; GREAT BRITAIN; LIVER NEOPLASMS; ODDS RATIO; RISK ASSESSMENT; STATISTICAL MODEL;

AGED; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER DISEASES; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT;

EID: 84924146464     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv009     Document Type: Article

References (46)

1. Ferlay J, Soerjomatarm I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. http://globocan.iarc.fr. Accessed July 15, 2014.
2. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15(2):223-243, vii-x.
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485-1491.
4. Welzel TM, Graubard BI, Quraishi S, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108(8):1314-1321.
5. Tanaka Y, Kurbanov F, Mano S, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006;130(3):703-714.
6. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
7. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275(1):55-60.
8. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer. 2008;44(15):2122-2132.
9. Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of casecontrol studies. Eur J Cancer Prev. 2008;17(3):259-268.
10. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9(1):10-19.
11. Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64(1):102-146.
12. Chiu HF, Ho SC, Chen CC, et al. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol. 2011;106(5):894-898.
13. Lai SW, Liao KF, Lai HC, et al. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol. 2013;28(6):485-492.
14. Leung HW, Chan AL, Lo D, et al. Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf. 2013;12(1):19-27.
15. Tsan YT, Lee CH, Ho WC, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol. 2013;31(12):1514-1521.
16. Tsan YT, Lee CH, Wang JD, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30(6):623-630.
17. El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136(5):1601-1608.
18. Friedman GD, Flick ED, Udaltsova N, et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008;17(1):27-36.
19. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114(4):643-647.
20. Khurana V, Saluja A, Caldito G, et al. Statins are protective against hepatocellular cancer in patients with hepatitis C virus infection: half a million U.S. veterans' study. Gastroenterology. 2005;128:A714.
21. Marelli C, Gunnarsson C, Ross S, et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol. 2011;58(5):530-537.
22. McGlynn KA, Divine GW, Sahasrabuddhe VV, et al. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol. 2014;38(5):523-527.
23. Lund JL, Montomoli J. Common flaws in pharmacoepidemiologic study design and analysis. J Clin Oncol. 2013;31(32):4161-4162.
24. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374-380.
25. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. QJM. 1998;91(6):445-452.
26. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766-768.
27. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23(5):686-689.
28. Jick H, Jick S, Derby LE, et al. Calcium-channel blockers and risk of cancer. Lancet. 1997;349(9051):525-528.
29. Sahasrabuddhe VV, Gunja MZ, Graubard BI, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012;104(23):1808-1814.
30. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116(8):1938-1946.
31. Pradelli D, Soranna D, Scotti L, et al. Statins and primary liver cancer: a metaanalysis of observational studies. Eur J Cancer Prev. 2013;22(3):229-234.
32. Singh S, Singh PP, Singh AG, et al. Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. Gastroenterology. 2013;144(2):323-332.
33. Sato S, Ajiki W, Kobayashi T, et al. Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol. 2006;16(5):201-206.
34. Matsushita Y, Sugihara M, Kaburagi J, et al. Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. Pharmacoepidemiol Drug Saf. 2010;19(2):196-202.
35. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7(1):e29849.
36. Lipkin SM, Chao EC, Moreno V, et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila). 2010;3(5): 597-603.
37. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376(9756):1916-1922.
38. Bader T. Yes! Statins can be given to liver patients. J Hepatol. 2012;56(2):305-307.
39. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425-430.
40. Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys. 1996;325(2):242-248.
41. Garcia-Ruiz C, Morales A, Fernandez-Checa JC. Statins and protein prenylation in cancer cell biology and therapy. Anticancer Agents Med Chem. 2012;12(4):303-315.
42. Jackson SM, Ericsson J, Edwards PA. Signaling molecules derived from the cholesterol biosynthetic pathway. Subcell Biochem. 1997;28:1-21.
43. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumorspecific apoptosis. Leukemia. 2002;16(4):508-519.
44. Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 1999;96(14):7797-7802.
45. Dorobantu C, Macovei A, Lazar C, et al. Cholesterol depletion of hepatoma cells impairs hepatitis B virus envelopment by altering the topology of the large envelope protein. J Virol. 2011;85(24):13373-13383.
46. Bonovas S, Sitaras NM. Statins and cancer risk: a confounded association. Gastroenterology. 2009;137(2):740;author reply 740-741.